Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It

‘The Regulatory Path Has To Be Determined. It Doesn’t Exist Today’

Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that both parties feel might be almost immune to biosimilar competition.

NEW YORK, NEW YORK - DECEMBER 05: CEO of Pfizer Inc. Albert Bourla, DVM, Ph.D. attends 2019 Forbes Healthcare Summit at the Jazz at Lincoln Center on December 05, 2019 in New York City. (Photo by Steven Ferdman/Getty Images)
• Source: Steven Ferdman/Getty Images (Steven Ferdman/Getty Images)

Pfizer’s recent determination to pay $43bn for antibody-drug conjugate (ADC) pioneer Seagen, the largest pharmaceutical deal since AbbVie’s $63bn takeover of Allergan three years ago, stems in part from the remote chance that a biosimilar sponsor would ever be motivated or indeed able to replicate the groundbreaking medicines.

This is according to Pfizer’s CEO Albert Bourla, who spearheaded efforts to turn rumors into reality earlier this week with Pfizer’s all-cash agreement for Seagen, including $31bn of fresh long-term debt

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin